Bavarian Nordic A/S (OTCMKTS:BVNRY) Short Interest Down 54.5% in May

Bavarian Nordic A/S (OTCMKTS:BVNRY – Get Rating) was the target of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 500 shares, a drop of 54.5% from the April 30th total of 1,100 shares. Based on an average daily volume of 600 shares, the short-interest ratio is presently 0.8 days.

Shares of OTCMKTS BVNRY opened at $10.72 on Friday. Bavarian Nordic A/S has a 1 year low of $5.85 and a 1 year high of $19.25. The firm has a 50-day simple moving average of $7.94 and a two-hundred day simple moving average of $10.69.

Bavarian Nordic A/S (OTCMKTS:BVNRY – Get Rating) last announced its quarterly earnings data on Friday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The business had revenue of $83.65 million for the quarter, compared to analyst estimates of $93.33 million. On average, sell-side analysts predict that Bavarian Nordic A/S will post -1.07 earnings per share for the current fiscal year.

Several analysts have issued reports on BVNRY shares. Zacks Investment Research raised shares of Bavarian Nordic A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, May 24th. Cowen downgraded shares of Bavarian Nordic A/S from an “outperform” rating to a “market perform” rating in a research note on Friday, February 4th.

About Bavarian Nordic A/S (Get Rating)

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

See Also